foto1 foto2 foto3 foto4 foto5

Our news

  • 18/07/2019: Pharegis implemented optimized procedures for state registration of pharmaceuticals in Eurasian Economic Union.
  • 20/06/2019: Pharegis updated timelines and practical approaches for Russian and EEU GMP inspection applications and procedures.
  • 03/04/2019:  Renewed general monographs of Russian state pharmacopeia XIV ed. have been analyzed.

Contact us


Regulatory Events Russia

March 2020
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31 1 2 3 4
April 2020
29 30 31 1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 1 2

Russian Regulatory News

Drug registration in Russia, biosimilars registration, fast generic registration, vaccines registration, pharma regulatory service in Russia by CRO Pharegis

State registration of pharmaceuticals in Russia

Obtaining registration of a pharmaceutical in Russia is quite a challenge. Both local and international companies that faced Russian drug regulatory system can confirm that.

Formal requirements that are stated in Russian core law “On drug circulation” in many cases are not specific. Understanding of those (and many more) legal paragraphs is critically  important to any company that is planning to register and market their products in Russia.

Russian National Pharmacopeia is quite specific and every product quality control methods should be interpreted according to its requirements and format in official compilation on Russian where no mistake or inaccuracy is allowed. Also, state quality control institutions in Russia in some cases can not perform particular methods described in the original dossier.

Russian regulatory system has unique features like obligatory clinical studies incorporated to a pharmaceutical registration procedure, extensive preclinical studies program for registration and full quality control of first imported batches after registration.

We are quite proud to have full understanding ot every regulatory requirement in its context and practical importance. Pharegis team has more than 50 years of total experience in drug registration in Russia providing full cycle service – from feasibility analysis of particular registration project, dossier gap analysis and registration timeline schedule - to managing preclinical and clinical studies and any quality control questions that can arise.


News and press releases

  • EMA advises continued use of medicines for hypertension, heart or kidney disease during COVID-19 pandemic, , 27/03/2020
  • No change to product information for breast cancer medicine Tyverb following re-assessment of data, CHMP, 27/03/2020
  • Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 March 2020, CHMP, 27/03/2020
  • New gene therapy to treat spinal muscular atrophy, , 27/03/2020